The pharma is based in Europe. The company forms relationships with early-stage biotech companies, usually structured in the form of rights (worldwide, world excluding US & Japan, or regional rights), co-marketing, or R&D collaborations. The company may also consider participation in equity financing rounds. Recently, the company has entered an agreement to develop an incubator which is expected to open in 2023. The company is open to partnering with companies globally.

Currently, the company focuses on 5 disease areas: oncology, CNS, immune-inflammation (early-stage); cardiovascular disease, and metabolic disease (late-stage).

Within oncology, the company is interested in apoptosis (BCL2 family), novel oncogenes/oncogene stability regulators, epigenetic regulators (with biomarker validation), synthetic lethality associated with genetic defect, stroma/tumor microenvironment, T cell activation, immunosuppression, and innate immunity. In terms of modalities, the firm is primarily looking at small molecules (discovery to early clinical stage) and monoclonal antibodies/bispecifics (early clinical stage).

Within CNS, the firm is looking for small molecules, oligonucleotides, or PROTAC that address rare synucleinopathies, rare tauopathies, repeat expansion diseases, and amyotrophic lateral sclerosis by menas of clearance of toxic proteins and targeted degradation, as well as regulation of transcription and translation of targets. The company is not interested in epilepsy, multiple sclerosis, pain, psychiatry, or infectious diseases, and is currently not seeking antibodies, cell therapy, or vaccines.

Within immuno-inflammatory diseases, the company is most interested in lupus, systemic sclerosis, Sjögren syndrome, and other chronic inflammatory and fibrotic diseases that share similar pathophysiological mechanisms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a New York-based Life Sciences investment firm. Typical allocations are up to $4M in projects. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities in the US and Canada, and Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices and diagnostics. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts.

The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, health IT, and biosimilars/generics are not of interest. The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives, the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with unmatched track-record of success and strong credibility. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm founded in 2020 and is located in Texas. The firm is different from a traditional VC in that it focuses on investing, building and scaling life science start ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by 35 angel groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. The firm’s goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. The firm is open to global opportunities.

The firm focus on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.